Drug companies steaming about ICER report

An Institute for Clinical and Economic Review report asserting that “unjustified” price increases cost the U.S. healthcare system $1.7 billion in 2020 generated headlines and fueled calls for national and state legislation to restrain drug prices.

Drug companies and an industry-funded think tank are pushing back, arguing that in its third annual Unsupported Price Increase Report ICER disregarded evidence justifying price increases for specific drugs and tweaked its methodology to arrive at a predetermined result. ...